PMID- 38148005
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240304
IS  - 1447-0756 (Electronic)
IS  - 1341-8076 (Linking)
VI  - 50
IP  - 3
DP  - 2024 Mar
TI  - Anti-inflammatory, antioxidant, antiangiogenic, and therapeutic efficacy of 
      neroli oil in rats with endometriotic lesions.
PG  - 516-525
LID - 10.1111/jog.15866 [doi]
AB  - INTRODUCTION: Endometriosis is a serious health problem among women of 
      reproductive age, with pelvic pain and infertility. Given the limited success of 
      current treatments, this study explores Neroli oil (N.O.) effects on 
      inflammation, oxidation, angiogenesis, and tissue remodeling implicated in 
      endometriosis. MATERIALS AND METHODS: Albino Wistar female rats were used to 
      simulate an endometriosis model. Groups were established for comparison: a 
      control, an endometriosis model, a N.O.-treated group, and a N.O.-treated group 
      postendometriosis induction. The study focused on Tumor necrosis factor-alpha 
      (TNF-alpha), Interleukin 6, Interleukin 8, vascular endothelial growth factor (VEGF), 
      myeloperoxidase, Matrix metalloproteinase-1 (MMP-1), nitric oxide, superoxide 
      dismutase, catalase, and anti-mullerian hormone values, as well as 
      histopathological evaluations of endometriotic foci. RESULTS: AMH values showed a 
      significant increase in the endometriosis group treated with N.O. compared with 
      the endometriosis group (p < 0,01).A statistically significant decrease was found 
      in MMP-1 level in the endometriosis group that underwent N.O. (p < 0.001). 
      Increased CAT (p < 0.0001) and decrease in nitric oxide (p < 0.01) are found in 
      N.O.-treated endometriosis group. TNF-alpha levels in the endometriosis group showed 
      a statistically significant increase in the endometriosis group when compared 
      with the control and sham group (p < 0.001, p < 0.01 respectively). In our study, 
      a statistically significant increase was observed in VEGF levels (p < 0.001) in 
      endometriosis group and significant decrease in the N.O. administered 
      endometriosis model group. Groups treated with N.O. showed decreased inflammation 
      and congestion scores. Histopathological assessments demonstrated reduced 
      inflammation and tissue remodeling signs in endometriotic foci. CONCLUSION: This 
      study highlights the potential of N.O. in the treatment of endometriosis, owing 
      to its anti-inflammatory, antioxidant, and antiangiogenic properties that can 
      disrupt chronic processes. Our findings lend support to utilization of herbal 
      remedies for the management of endometriosis, thereby emphasizing the necessity 
      for additional comprehensive investigations in the future.
CI  - (c) 2023 Japan Society of Obstetrics and Gynecology.
FAU - Canday, Mujde
AU  - Canday M
AUID- ORCID: 0000-0002-0164-2764
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Kafkas University, 
      Kars, Turkey.
FAU - Yurtkal, Aslihan
AU  - Yurtkal A
AUID- ORCID: 0000-0001-6173-3994
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Kafkas University, 
      Kars, Turkey.
FAU - Makav, Mustafa
AU  - Makav M
AUID- ORCID: 0000-0003-1879-8180
AD  - Department of Physiology, Faculty of Veterinary, Kafkas University, Kars, Turkey.
FAU - Kuru, Mushap
AU  - Kuru M
AUID- ORCID: 0000-0003-4409-251X
AD  - Department of Obstetrics and Gynecology, Faculty of Veterinary, Kafkas 
      University, Kars, Turkey.
LA  - eng
GR  - 2022-TS-34/Kafkas University Scientific Research Projects/
PT  - Journal Article
DEP - 20231226
PL  - Australia
TA  - J Obstet Gynaecol Res
JT  - The journal of obstetrics and gynaecology research
JID - 9612761
RN  - 0 (Antioxidants)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 3.4.24.7 (Matrix Metalloproteinase 1)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 80497-65-0 (Anti-Mullerian Hormone)
SB  - IM
MH  - Humans
MH  - Rats
MH  - Animals
MH  - Female
MH  - *Antioxidants/pharmacology
MH  - Vascular Endothelial Growth Factor A
MH  - Matrix Metalloproteinase 1
MH  - *Endometriosis/drug therapy
MH  - Nitric Oxide
MH  - Tumor Necrosis Factor-alpha
MH  - Anti-Inflammatory Agents/pharmacology/therapeutic use
MH  - Inflammation
MH  - Rats, Wistar
MH  - Anti-Mullerian Hormone
OTO - NOTNLM
OT  - angiogenesis
OT  - endometriosis
OT  - endometriosis treatment
OT  - herbal medicine
OT  - inflammation
OT  - neroli oil
OT  - oxidative stress
OT  - rat model
OT  - tissue remodeling
EDAT- 2023/12/27 00:41
MHDA- 2024/03/04 06:46
CRDT- 2023/12/26 20:03
PHST- 2023/07/14 00:00 [received]
PHST- 2023/12/11 00:00 [accepted]
PHST- 2024/03/04 06:46 [medline]
PHST- 2023/12/27 00:41 [pubmed]
PHST- 2023/12/26 20:03 [entrez]
AID - 10.1111/jog.15866 [doi]
PST - ppublish
SO  - J Obstet Gynaecol Res. 2024 Mar;50(3):516-525. doi: 10.1111/jog.15866. Epub 2023 
      Dec 26.